CUPERTINO, Calif. (Reuters) – Apple Inc introduced its largest-ever iPhone and a watch that detects heart problems on Wednesday in an attempt to get customers to upgrade to more expensive devices in the face of stagnant global demand for smartphones.
The relatively small changes to its lineup, following last year’s overhauled iPhone X, were widely expected by investors, who sent the company’s shares down 1.2 percent to $221.07.
The strategy has been successful, helping Apple’s stock up more than 30 pct this year and making it the first publicly traded U.S. company to hit a market value of more than $1 trillion.
Apple’s new iPhone XS, pronounced “ten S,” has a 5.8-inch (14.7-cm) screen, and starts at $999. The XS Max, the largest iPhone to date and one of the biggest on the market, has a 6.5-inch (16.5-cm) screen, and starts at $1,099.
“They have finally added a larger-screen phone so that they can directly compete with the Galaxy Note9 products,” Gartner analyst Annette Zimmermann said at the event at Apple’s Silicon Valley headquarters, referring to rival Samsung Electronics, which has led the trend toward big-screen phones.
“The larger screen will be very important in China to turn around the trend there, because they have lost some share in the last few years, partly because of screen size,” she added.
Apple also introduced a lower-cost 6.1-inch (15.5 cm) iPhone XR made of aluminum, starting at $749.
(Graphic: Apple stock performance six months ahead of each iPhone launch: reut.rs/2CJ8fgI)
The iPhone Xs Max’s display size is 26 percent larger than the previous largest iPhone display, marking the largest increase in screen size since 2014, wrote analyst Gene Munster of Loup Ventures in a note.
This year’s three top phones are all more expensive than last year’s models.
With two of them starting at $999 or higher in the United States, Apple appears to be taking advantage of a strong U.S. economy, low unemployment, and rising household wealth. The median U.S. household income rose for a third straight year in 2017 to the highest on record since 1967 by one measure, government data showed on Wednesday.
MEDICAL DEVICE MARKET
Looking for ways to lessen reliance on phones, which represent more than 60 percent its revenue, Apple opened its event by announcing the new Apple Watch Series 4 with edge-to-edge displays, like its latest phones, which are more than 30 percent bigger than displays on current models.
It is positioning the new watch as a more comprehensive health device, able to take an electrocardiogram to detect an irregular heartbeat and start an emergency call automatically if it detects a user falling down, potentially appealing to older customers.
The U.S. Food and Drug Administration said it worked with Apple to develop apps for the Apple Watch and has been taking steps to ease the regulatory pathway for companies seeking to create digital healthcare products.
“This is a pretty big deal,” said healthcare tech analyst Ross Muken at Evercore. “This update really establishes the company’s increasing efforts to push the watch as a serious medical device. Apple seems to be diving into heart disease first, the most common cause of death around the world, making serious moves as a health company.”
Shares of fitness device rival Fitbit Inc fell 6.9 percent after the Series 4 announcement.
Apple’s event was held at the Steve Jobs Theater at its new circular headquarters in Cupertino, California, named after the company’s co-founder who wowed the world with the first iPhone in 2007.
Executives made no mention of a wireless charging mat, or content deals for Apple TV, as some industry analysts had expected.
“We all knew this was going to be a transitional but not transformational phone update,” said Trip Miller, managing partner at hedge fund Gullane Capital, which owns Apple shares.
(Graphic: Apple’s growth seen slowing: reut.rs/2CS6xt8)
Reporting by Sonam Rai in Bengaluru and Stephen Nellis in Cupertino, California; Additional reporting by Supantha Mukherjee in Bengaluru, Nadine Schimroszik in Berlin and Yasmeen Abutaleb in Washington; Writing by Bill Rigby; Editing by Bernard Orr and Nick Zieminski